Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evaxion A/S ADR (EVAX)

Evaxion A/S ADR (EVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Evaxion to Showcase Phase 2 Data of AI-Powered Cancer Vaccine at ESMO 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Evaxion Biotech...

EVAX : 4.55 (-5.01%)
Evaxion Unveils Automated Vaccine Design Module

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Evaxion Biotech...

EVAX : 4.55 (-5.01%)
Evaxion to Present New Data on AI-Designed Cancer Vaccine at SITC 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Evaxion Biotech...

EVAX : 4.55 (-5.01%)
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

Issued on behalf of Oncolytics Biotech Inc.

ONCY : 1.0100 (+3.80%)
AGEN : 3.34 (-9.24%)
CELC : 106.96 (+1.60%)
LYEL : 23.76 (+3.62%)
EVAX : 4.55 (-5.01%)
ONC.TO : 1.42 (+2.16%)
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

/CNW/ -- Equity Insider News Commentary – The average age of cancer patients is getting younger, as experts are urgently examining the rise of early-onset...

ONCY : 1.0100 (+3.80%)
AGEN : 3.34 (-9.24%)
CELC : 106.96 (+1.60%)
LYEL : 23.76 (+3.62%)
EVAX : 4.55 (-5.01%)
ONC.TO : 1.42 (+2.16%)
Stock Index Futures Mixed on Pressure from Rising Bond Yields, Oil Prices Rise After Saudi Output Cuts

June S&P 500 futures (ESM23) are up +0.01%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.25% this morning as market participants digested the U.S. debt ceiling agreement, while U.S. Treasury...

EVAX : 4.55 (-5.01%)
MRO : 28.55 (-1.28%)
DAWN : 10.16 (-3.24%)
ETRN : 12.42 (+0.57%)
MMM : 167.80 (-1.93%)
DBRG : 15.35 (+0.13%)
LULU : 201.87 (-1.53%)
OXY : 42.70 (-1.09%)
RAIN : 3.36 (+0.90%)
ESM23 : 4,453.35s (+0.61%)
VOLCB.S.DX : 32.240 (-2.98%)
NQM23 : 15,316.61s (+0.85%)
Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update

Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLCAnnounced successful production of personalized cancer immunotherapies for...

EVAX : 4.55 (-5.01%)
Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10

COPENHAGEN, Denmark, July 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 4.55 (-5.01%)
Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target

COPENHAGEN, Denmark, June 30, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 4.55 (-5.01%)
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer

COPENHAGEN, Denmark, June 23, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 4.55 (-5.01%)

Barchart Exclusives

The Most Overlooked Dividend Kings to Buy in 2026
These overlooked Dividend Kings offer accelerating dividend growth, improving profitability, and long-term bullish momentum that income investors can rely on for consistent returns in 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar